- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04394078
Impact of COVID-19 Pandemic on Depression and Quality of Life
June 8, 2020 updated by: Begüm Okudan, Okan University
Impact of COVID-19 Pandemic on Depression and Quality of Life: Cross Sectional Study on Turkish Society and Suggestions on Potential Solution
It is aimed to investigate the depression and quality of life of Turkish society caused by Covid-19 pandemic and reveal the relationship between them
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Study hypothesis that people are tend to be depressed and the quality of life is affected negatively by Covid-19 pandemic.
Although Turkey has affected moderately, the immediate change on depression and quality of life observable and measurable.
It is aimed to investigate the depression and quality of life of Turkish society caused by Covid-19 pandemic and reveal the relationship between them.
According to existing data and perspective of psychology and physiotherapy, potential solutions will be aligned.
Study Type
Observational
Enrollment (Actual)
543
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Istanbul, Turkey, 34959
- Okan University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
15 years to 65 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
The population of the individuals between 15 - 65 ages in Turkey is 56.391.925
people.
It is calculated that there are 42.463.119
individuals cover the criterion as universe of the study.
Description
Inclusion Criteria:
- being Turkish
- understanding Turkish
- currently living in Turkey
- being between the age of 15 - 65
- being literate
- have internet access
Exclusion Criteria:
- being diagnosed with a psychological disorder before the pandemic
- having missing value on outcome measures
- giving incomprehensible answering
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Turkish society
Individuals speak Turkish and lives in Turkey, ages between 15 - 65, literate and with internet access
|
Volunteer individuals enrolled the study after approval an online informed consent form.
Sociodemographic data of the participants recorded as an online survey.
Then, patient reported outcomes were used to assess depression (Zung depression Scale) and quality of life (WHO Qualiy of Life - Bref version).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sociodemographic information form
Time Frame: two months after Covid 19 recognised as pandemic
|
Participants are asked to give information about: age, gender, educational status, height, weight, occupation, working status, city inhabited, whether they live alone or with someone, whether they have a chronic disease, have a pet, do physical activity, eat healthy and sufficient, have qualified sleep, whether they are supported economically.
|
two months after Covid 19 recognised as pandemic
|
Zung Depression Scale
Time Frame: two months after Covid 19 recognised as pandemic
|
Zung depression scale, developed by Zung (Zung, 1965), is patient rating depression scale, was used to asses four domains related to depression; somatic, mood disorders, psychomotor and psychological disorders.
Each question is rated on a 4-point Likert scale (0- never, 1- sometimes, 2- frequently, 3- always).
Scale contains 10 straight 10 reverse questions.
The total score is calculated from the raw score obtained (total score = (raw score / 80) * 100).
Accordingly, scores less than 50 are normal or no psychopathology; between 50 and 59 points indicates mild level, between 60 and 69 points indicate moderate level and 70 and above points indicate severe level depression (Thurber et al., 2002).
The validity reliability of the scale was studied on Turkish society (Gencdogan & Nihal, 2011)
|
two months after Covid 19 recognised as pandemic
|
World Health Organization Quality of Life - Bref
Time Frame: two months after Covid 19 recognised as pandemic
|
World Health Organization Quality of Life Bref is the short version of the WHOQOL-100 to assess the health-related quality of life (Harper et al., 1998), which has efficient psychometric properties, valid and reliable for Turkish society (Eser et al., 1999).
It is essential for epidemiological survey and international report has built for psychometric properties for 26 country where Turkey within (Skevington et al., 2004).
It has 4 domains; physical health, psychology, social relations and environment.
Each question is answered on a 5-point Likert scale.
The raw score is converted into a percentage system.
The quality of life is interpreted as good as it gets closer to 100% (Akvardar et al., 2006).
|
two months after Covid 19 recognised as pandemic
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 6, 2020
Primary Completion (Actual)
May 18, 2020
Study Completion (Actual)
May 18, 2020
Study Registration Dates
First Submitted
May 18, 2020
First Submitted That Met QC Criteria
May 18, 2020
First Posted (Actual)
May 19, 2020
Study Record Updates
Last Update Posted (Actual)
June 11, 2020
Last Update Submitted That Met QC Criteria
June 8, 2020
Last Verified
June 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Mood Disorders
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- Depression
- Depressive Disorder
- COVID-19
Other Study ID Numbers
- 56665618-204.01.07
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
Data are stored by researches, if needed for scientific purposes, it can be discussed to share .
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
-
Lawson Health Research InstituteTerminated
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Federal Research Center of Fundamental and Translational...CompletedDepression Moderate | Depression MildRussian Federation
Clinical Trials on Online survey
-
Tomsk National Research Medical Center of the Russian...RecruitingCOVID-19 | Risk Factors | Polypharmacy | Drug Interactions | Self MedicationRussian Federation
-
Jaseng Medical FoundationCompletedFractures, Bone | Medicine, Korean TraditionalKorea, Republic of
-
Medical University of GrazRecruitingPsychological Distress | Corona Virus Infection | Psychiatric DisorderAustria
-
NYU Langone HealthCompleted
-
CHDI Foundation, Inc.IQVIA CompanyCompletedHuntington's DiseaseUnited States
-
McGill UniversityJuvenile Diabetes Research Foundation; Canadian Institutes of Health Research...Completed
-
Gazi UniversityCompletedEvaluation of Quality of Life in Patients With Type 1 Diabetes Mellitus During the Covid-19 PandemicCovid19 | Type 1 Diabetes MellitusTurkey
-
Okan UniversityCompletedCOVID | Isolation, SocialTurkey
-
Hasselt UniversityRecruitingPhysical Activity | Chronic Musculoskeletal Disease | Exercise Intensity | Online SurveyBelgium